Certificate pursuant to Regulation 74(5) of SEBI (D&P) Regulations 2018 for the quarter ended on 31-03-2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Jenburkt Pharmaceuticals has submitted a routine quarterly compliance certificate to BSE for the quarter ended 31 March 2026. The certificate was issued by the company's Registrar and Transfer Agent, Bigshare Services Pvt. Ltd., on 6 April 2026. It confirms that all securities received from depository participants for dematerialization during the quarter were properly processed, with certificates mutilated, cancelled, and the depository's name recorded as the registered owner in the company's register of members within the required 15-day window. The filing was signed by Ashish R. Shah, Vice President & Company Secretary, and is purely a procedural compliance requirement under SEBI's Depositories and Participants Regulations, 2018.
This is a standard housekeeping filing with no material impact on the company's financials, operations, or shareholders. Investors can ignore this for stock price or fundamental analysis purposes.